«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

29卷

期数:

2023年02期

页码:

148-152

栏目:

基础医学

出版日期:

2023-03-20

文章信息/Info

Title:

Effect and mechanism of IL-17A on the progression of ovarian cancer

文章编号:

1006-8147（2023）02-0148-05

作者:

郑小燕; 郁春艳; 刘俊汝; 刘子璇; 陈思琦; 邓为民

天津医科大学基础医学院免疫学系，国家教育部免疫微环境与疾病重点实 验 室，天津300070

Author(s):

ZHENG Xiao-yan; YU Chun-yan; LIU Jun-ru; LIU Zi-xuan; CHEN Si-qi; DENG Wei-min

Department of Immunology，School of Basic Medical Sciences，Tianjin Medical University，Key Laboratory of Diseases and Microenvironment of Ministry of Education of China，Tianjin 300070，China

关键词:

IL-17A; 卵巢癌; FABP4

Keywords:

sovarian cancer; IL-17A; FABP4; progression of cancer

分类号:

R737.31

DOI:

-

文献标志码:

A

摘要:

目的：采用动物实验和临床标本探讨白细胞介素-17A（IL-17A）对卵巢癌（OvCa）进展的影响，并探索相应机制。方法：以C57BL/6遗传背景的野生型（WT）小鼠和IL-17A缺陷型（IL-17A-/-）小鼠为研究对象，原位注射相同基因背景来源的小鼠OvCa细胞系ID8构建卵巢原位种植瘤模型，观察IL-17A对小鼠OvCa生长转移的影响。应用Western印迹检测WT小鼠和IL-17A-/-小鼠肿瘤组织中信号转导和转录激活因子3（STAT3）、磷酸化STAT3（p-STAT3）、脂肪酸结合蛋白4（FABP4）表达情况，以探讨IL-17A促进OvCa进展的机制。收集OvCa患者临床病理组织切片标本，应用免疫组化分析IL-17A、FABP4表达与OvCa进展的相关性。结果：WT小鼠造模部位卵巢明显肿大，与周围组织黏连，其表面可见若干瘤结节；IL-17A-/-小鼠卵巢肿大，与周围组织无黏连，表面瘤结节较少。与WT小鼠相比，IL-17A-/-小鼠腹腔瘤结节显著减少（t=5.132，P<0.05）。Western印迹结果显示与WT小鼠相比，IL-17A-/-小鼠肿瘤组织中p-STAT3、FABP4蛋白表达显著降低（均P＜0.05）。OvCa患者临床病理标本显示IL-17A、FABP4表达与癌症FIGO分期、转移相关（均P＜0.05），并且在OvCa患者中IL-17A与FABP4表达也具有一定相关性（P＜0.05）。结论：动物实验和临床标本证实IL-17A通过上调FABP4表达促进OvCa进展。

Abstract:

Objective：Animal experiments and clinical specimens were applied to investigate the effect of interleukin-17A（IL-17A） on the progression of ovarian cancer（OvCa），and to explore the corresponding mechanism. Methods: Wild-type（WT）mice and IL-17A-deficient（IL-17A-/-）mice with C57BL/6 genetic background were used as the research objects，and the mouse OvCa cell line ID8 derived from the same genetic background was injected in situ to construct ovarian orthotopic tumor implantation model to observe the effect of IL-17A on the growth and metastasis of OvCa in mice. Western blotting was used to detect the expression of signal transducer and activator of transcription 3（STAT3），phosphorylated STAT3（p-STAT3）and fatty acid-binding protein 4（FABP4）in tumor tissues of WT mice and IL-17A-/-mice to explore the mechanism of IL-17A promoting OvCa progression. The clinicopathological specimens of OvCa patients were collected and immunohistochemistry was used to analyze the correlation between the expression of IL-17A，FABP4 and OvCa progression. Results: The ovaries of WT mice were obviously enlarged and adhered to the surrounding tissues，and several nodules were seen on the surface of the ovaries. The ovaries of IL-17A-/-mice were enlarged，without adhesion to the surrounding tissues，and there were few tumor nodules on the surface. Compared with WT mice，the tumor nodules in the peritoneal cavity of IL-17A-/-mice were significantly reduced （t=5.132，P<0.05）. Western blotting showed that compared with WT mice，the protein expressions of p-STAT3 and FABP4 of tumor nodules in IL-17A-/- mice were significantly decreased（both P<0.05）.The clinicopathological specimens of OvCa showed that the expression of IL-17A and FABP4 was correlated with FIGO stage and metastasis of cancer（both P<0.05），and the expression of IL-17A was also correlated with FABP4 in OvCa patients（P<0.05）. Conclusion: Results of animal experiments and clinical specimens confirmed that IL-17A promoted OvCa progression by upregulating the expression of FABP4.

参考文献/References:

[1] NIEMAN K M，KENNY H A，PENICKA C V，et al. Adipocytes pro－mote ovarian cancer metastasis and provide energy for rapid tumor growth[J]. Nat Med，2011，17（11）：1498-1503.
[2] LADANYI A，MUKHERJEE A，KENNY H A，et al. Adipocyte-in－duced CD36 expression drives ovarian cancer progression and metas－tasis[J]. Oncogene，2018，37（17）：2285-2301.
[3] MUKHERJEE A，CHIANG C Y，DAIFOTIS H A，et al. Adipocyte-induced FABP4 expression in ovarian cancer cells promotes metas－tasis and mediates carboplatin resistance[J]. Cancer Res，2020，80（8）：1748-1761.
[4] MUKHERJEE A，BILECZ A J，LENGYEL E. The adipocyte mi－croenvironment and cancer[J]. Cancer Metastasis Rev，2022，41（3）：575-587.
[5] GHARPURE K M，PRADEEP S，SANS M，et al. FABP4 as a key de－terminant of metastatic potential of ovarian cancer[J]. Nat Commun， 2018，9（1）：2923.
[6] TUCKER S L，GHARPURE K，HERBRICH S M，et al. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer[J]. Clin Cancer Res，2014，20（12）：3280-3288.
[7] CHEHIMI M，VIDAL H，ELJAAFARI A. Pathogenic role of IL-17-producing immune cells in obesity，and related inflammatory dis－eases[J]. J Clin Med，2017，6（7）：68.
[8] RAZI S，BARADARAN NOVEIRY B，KESHAVARZ-FATHI M，et al. IL-17 and colorectal cancer：from carcinogenesis to treatment[J]. Cytokine，2019，116：7-12.
[9] MCGEACHY M J，CUA D J，GAFFEN S L. The IL-17 family of cy－tokines in health and disease[J]. Immunity，2019，50（4）：892-906.
[10] LIU C，LIU R，WANG B，et al. Blocking IL-17A enhances tumor re－sponse to anti-PD-1 immunotherapy in microsatellite stable col－orectal cancer[J]. J Immunother Cancer，2021，9（1）：e001895.
[11] BILSKA M，PAWLOWSKA A，ZAKRZEWSKA E，et al. Th17 Cells and IL-17 as novel immune targets in ovarian cancer therapy[J]. J Oncol，2020，2020：8797683.
[12] GREENHILL C. Role for IL-17A in adipocyte biology[J]. Nat Rev Endocrinol，2021，17（7）：383.
[13] CONNOLLY D C，HENSLEY H H. Xenograft and transgenic mouse models of epithelial ovarian cancer and non invasive imaging modali－ties to monitor ovarian tumor growth in situ：applications in evaluat－ing novel therapeutic agents [J]. Curr Protoc Pharmacol，2009，45：chapter14：unit142.
[14] SIEGEL R L，MILLER K D，FUCHS H E，et al. Cancer statistics， 2022[J]. CA Cancer J Clin，2022，72（1）：7-33.
[15] SWIDERSKA J，KOZLOWSKI M，KWIATKOWSKI S，et al. Im－munotherapy of ovarian cancer with particular emphasis on the PD-1/PDL-1 as target points[J]. Cancers（Basel），2021，13（23）：6063.
[16] LHEUREUX S，BRAUNSTEIN M，OZA A M. Epithelial ovarian cancer：evolution of management in the era of precision medicine[J]. CA Cancer J Clin，2019，69（4）：280-304.
[17] KUROKI L，GUNTUPALLI S R. Treatment of epithelial ovarian can－cer [J]. BMJ，2020，371：m3773.
[18] DJOUSSE L，GAZIANO J M. Plasma levels of FABP4，but not FABP3，are associated with increased risk of diabetes [J]. Lipids， 2012，47（8）：757-762.
[19] MAKOWSKI L，BRITTINGHAM K C，REYNOLDS J M，et al. The fatty acid-binding protein，aP2，coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and Ikap－paB kinase activities[J]. J Biol Chem，2005，280（13）：12888-12895.
[20] HARJES U，BRIDGES E，GHARPURE K M，et al. Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4[J]. Oncogene，2017，36（7）：912-921.
[21] COFFELT S B，KERSTEN K，DOORNEBAL C W，et al. IL-17-pro－ducing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis[J]. Nature，2015，522（7556）：345-348.
[22] LI S，CONG X，GAO H，et al. Tumor-associated neutrophils induce EMT by IL-17a to promote migration and invasion in gastric cancer cells[J]. J Exp Clin Cancer Res，2019，38（1）：6.

相似文献/References:

[1]申彦,张新莹,师宜荃,等.Glut-1、HIF-1α及P53在卵巢癌中的表达及意义[J].天津医科大学学报,2013,19(05):383.
[2]周 闻,杨 臻,刘 民,等.抑癌基因ST7L对卵巢癌细胞增殖、细胞周期和裸鼠移植瘤的影响[J].天津医科大学学报,2016,22(05):373.
　ZHOU Wen,YANG Zhen,LIU Min,et al.Effects of ST7L on cell proliferation, cell cycle in ovarian cancer and tumour xenografts in nude mice[J].Journal of Tianjin Medical University,2016,22(02):373.
[3]范 丹,宋文静,张艳辉,等.PRRX1的表达对卵巢癌血管生成拟态形成及患者预后的影响[J].天津医科大学学报,2018,24(01):1.
　FAN Dan,SONG Wen-jing,ZHANG Yan-hui,et al.Effect of PRRX1 expression on VM formation and prognosis in ovarian cancer[J].Journal of Tianjin Medical University,2018,24(02):1.
[4]王雅蕾,王靖怡 综述,齐丽莎 审校.微环境在卵巢癌发生发展中的作用[J].天津医科大学学报,2020,26(03):288.
[5]李广宁 综述,曹文枫 审校.女性生殖系统双原发癌的研究进展[J].天津医科大学学报,2021,27(06):655.
[6]沈洋洋,牛秀珑,郁春艳,等.外源性IL-6 通过STAT3 通路促进卵巢癌细胞对顺铂 耐药[J].天津医科大学学报,2022,28(03):266.
　SHEN Yang-yang,NIU Xiu-long,YU Chun-yan,et al.Exogenous IL-6 promotes cisplatin resistance of ovarian cancer through STAT3 pathway[J].Journal of Tianjin Medical University,2022,28(02):266.
[7]徐灵灵,牛秀珑,张宏健,等.IL-17A促进卵巢癌顺铂耐药的体外机制探讨[J].天津医科大学学报,2018,24(03):192.
　XU Ling-ling,NIU Xiu-long,ZHANG Hong-jian,et al.Study on the underlying mechanisms of IL-17A promoting the cisplatin-based resistance of ovarian cancer[J].Journal of Tianjin Medical University,2018,24(02):192.
[8]李岩,牛秀珑,郁春艳,等.IL-17A可以促进卵巢癌的腹腔转移[J].天津医科大学学报,2020,26(06):518.
　LI Yan,NIU Xiu-long,YU Chun-yan,et al.IL-17A promotes intraperitoneal metastasis of ovarian cancer[J].Journal of Tianjin Medical University,2020,26(02):518.

备注/Memo

备注/Memo:

基金项目：国家自然科学基金（82273340）；京津冀基础研究合作专项（20JCZXJC00140）
作者简介： 郑小燕（1999-），女，硕士在读，研究方向：肿瘤免疫；
通信作者：邓为民，E-mail：dengweimin@tmu.edu.cn。

常用功能

更新日期/Last Update: 2023-04-30